FDA Reshuffles Office Of Generic Drugs To Improve Performance
Executive Summary
The generic drug industry can expect more streamlined reviews as a result of FDA's reorganization of the Office of Generic Drugs, according to the agency.
You may also be interested in...
Outgoing OGD Director Outlines Accomplishments During His Tenure
Gregory Geba highlights the strides the Office of Generic Drugs made in implementing the generic drug user fee program in his resignation announcement.
Generic Drugs Gain Status Boost Within CDER
More than just a bureaucratic shell game, the promotion of the Office of Generic Drugs to “super office” status signals CDER Director Janet Woodcock’s tightened focus on generic drugs.
FDA's Office of Medical Policy Grows Into A "Super Office"; DDMAC Gets A Promotion
The Office of Medical Policy now houses the Office of Prescription Drug Promotion (formerly DDMAC) and the newly created Office of Medical Policy Initiatives.